MSD closes $1.3bn EyeBio acquisition, plans pivotal trial for lead asset
Two months after MSD (Merck & Co) set its eye on acquiring Eyebiotech (EyeBio), the former has closed the deal,…
Two months after MSD (Merck & Co) set its eye on acquiring Eyebiotech (EyeBio), the former has closed the deal,…
Two years following a voluntary recall, Roche has relaunched Susvimo (ranibizumab injection) for use as an ocular implant for the…
Roche has received approval from the US Food and Drug Administration (FDA) for the Vabysmo (faricimab) 6.0mg single-dose prefilled syringe…
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has backed approval for Akantior (polihexanide), a…
MSD has announced a definitive agreement to acquire all outstanding shares of Eyebiotech (EyeBio) through a subsidiary for up to…
Turn Biotechnologies (Turn Bio) has entered an exclusive worldwide licensing agreement with HanAll Biopharma to develop therapies for age-related eye…
The US Food and Drug Administration (FDA) has approved Yesafili (aflibercept-jbvf) and Opuviz (aflibercept-yszy), two interchangeable biosimilars to the reference…
Formosa Pharmaceuticals has announced an exclusive licensing agreement with Tabuk Pharmaceuticals, granting the latter exclusive rights to commercialise the clobetasol…
LENZ Therapeutics has concluded its merger with Graphite Bio, forming a late-stage biopharmaceutical company dedicated to developing treatments for presbyopia.…
Sandoz has concluded the acquisition of the US biosimilar CIMERLI from Coherus BioSciences, marking a significant expansion of its ophthalmology…